Autopsy report · NCT00404703

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

“Primary (safety) endpoint reached”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 6 months before it stopped.
• 37 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Non-Small Cell Lung Cancer

Interventions

bevacizumab [Avastin]; Platinum-based chemotherapy

Participants

37

Sites

25

Countries

Australia, Belgium, Czechia, France, Hungary, Israel, Poland, Russia, Spain, Taiwan

Trials that died the same way

• Utilization of AMSC to Enhance Rotator Cuff Repair - Safety and Efficacy
  “Primary endpoint (safety) has been achieved” (90% match in meaning)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
  “Primary Endpoint met” (78% match in meaning)
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (78% match in meaning)
• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
  “Primary endpoint not achieved” (77% match in meaning)
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
  “Primary Endpoint not met” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.